LOS ANGELES–(BUSINESS WIRE)–$FENC #FENC—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fennec Pharmaceuticals Inc. (“Fennec” or “the Company”) (NASDAQ: FENC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fennec revealed in an August 11, 2020, press release that it had received a Complete Response Letter (“CRL”) from the FDA regarding its PEDMARK product. The Company reported that, “According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.” Based on this news, shares of Fennec fell by 34% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.